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ABSTRACT
Hemothorax is a condition where blood and pleural fluid become trapped between the lung(s)
and chest wall [1-3], typically from blunt or penetrating trauma [3]. Intrapleural fibrinolytic
therapy (IPFT) is a less invasive treatment option that is used to treat retained hemothorax,
allowing it to be broken down and drained through tube thoracostomy. IPFT has been
successfully modeled in a rabbit system, thus allowing the examination of various treatment
options pre-clinically. To help support the use of this animal model, blood halo assay (BHA) was
developed to assess the efficacy of various plasminogen activators for use with IPFT. The BHA
was optimized in a 96-well format using rabbit as well as human blood with both tPA or uPA
and it was found that a blood volume of 10 µL/well was optimal for reproducible halo clot
formation. In addition, comparison of halo clots formed with Tissue factor (Innovin) versus
thrombin/Ca2+ indicated the latter as providing the most reproducible results. Efficacy of human
tPA versus uPA (5 nM) in lysis of human and rabbit halo clots (with or without exogenous
human PLG 0-29 nM) was examined by monitoring the increase in the optical density within the
well at 510 nm (OD510) over time. Rates of clot lysis induced by tPA were found to be higher
than those obtained with uPA for both human and rabbit clots and were independent of the
presence of exogenously added PLG. Prepared clot halos in BHA plates were found to be stable
at 4ºC from 24 hrs to 6 days as determined by the similar rates of clot lysis obtained. The rate of
clot lysis was found to be reduced on day 7, and blood halos were found to be unstable on day 8,
possibly due to changes in the fibrin clot structure. The use of an I.DOT system to prepare BHA
plates was found to increase productivity, stability, and reproducibility. Overall, the BHA allows
rapid in vivo/ex vivo testing of different types of IPFT treatments and shows potential for
facilitating personalized treatment of retained hemothorax in a clinical setting.
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INTRODUCTION
Prevalence and Incidence of Hemothorax
Hemothorax has been defined as a collection of blood and pleural fluid in the space between
the lungs and the chest wall [1-3]. In the United States, at least 300,000 cases of hemothorax
occur each year [3, 4]. Causes of this condition include spontaneous occurrence, iatrogenesis,
and trauma with the majority of cases resulting from the latter two sources [3]. It has been
estimated that chest injury contributes to as much as 60% of hemothorax cases in the U.S.
annually [5]. Although pleural injury and infection have been recognized conditions for
centuries, the clinical identification of hemothorax and subsequent treatments have been credited
to John Hunter (1728-1793), a surgeon, who advocated intercostal drainage of hemothoraces [6].
This practice progressed in the late 1800s with the excising of hemothoraces using cannula and
trocar which became standard practice which was rapidly replaced by underwater seal drainage
until the early 2000s [6]. Within the last few decades, tube thoracostomy became the most
widely used treatment for hemothorax [1, 3, 6-10]. Further treatments and techniques are being
explored in order to increase efficiency and decrease morbidity and mortality associated with the
disease [3].
Development and Progression of Retained Hemothorax
A large volume of blood collected in the pleural space as part of a hemothorax can overwhelm
the anticoagulation cascade so that the excess blood cannot be efficiently reabsorbed by the body
[11]. When excessive clotting occurs as a result of an imbalance in the coagulation cascade, a
retained hemothorax is formed. Unfortunately, the literature presents controversial data regarding
the prevalence of retained hemothorax. The estimated incidence of retained hemothorax varies,
suggesting that this condition occurs in 4-20% of cases [5] or in as many as 10-35% of cases
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annually [12]. If the hemothorax is not removed, this can lead to other complications such as
fibrothorax and empyema. Fibrothorax is the presence of severe scarring of the lung which can
lead to a decrease in lung function and eventually lead to pneumonia and empyema [5, 13, 14].
Empyema is an infection of the pleural space which results in pleural effusion [14, 15].
Excessive pleural effusion can progress to fibrin deposition, fibroblast proliferation, and scar
formation resulting in serious illness and even death [15]. In as many as 20-30% of empyema
cases, initial treatment fails [16]. Therefore, it is crucial that the incidence of a hemothorax be
properly ascertained in order to prevent further complications.
Detection of Hemothorax
Detection of hemothorax on chest x-ray (CXR), ultrasound (US), or computed tomography
(CT) scan should be accompanied by a measure of the peripheral blood hematocrit of the pleura
to identify the presence of effusion in the pleural space [3, 17]. The detectable threshold for
perceived hemothorax should include a hematocrit greater than 50% in acute cases [1-3].
However, the presence of a retained hemothorax is indicated by a volume of clot greater than
500 mL with a hematocrit of 25-50% that cannot be removed through a simple thoracostomy [1,
3, 6].
The detection and treatment of hemothorax has only become standardized within the last few
decades. Current diagnostic techniques include CXR which is the most widely used technique
(Figure 1) [4]. However, it should be noted that the reliability of CXR is restricted to the upright
position as placing patients in the supine position has proven ineffective for detection of a
hemothorax due to distribution of fluid in the pleural space [3, 5]. It has also been indicated that
CXR even in the upright position may be inadequate for identification of hemothorax due to the
possibility of obstruction by surrounding organs and such as the diaphragm and abdominal
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viscera [5]. The literature indicates that in most instances CT currently provides the most reliable
form of detection of hemothorax currently available [1, 3, 6]. However, it has also been
suggested that this technique is costly, not always available, increases radiation exposure, and
relies on transportation of the patient [18]. Therefore, while US and CT are preferable methods
of detection of hemothorax, these methods are not always available [6, 18]. When US and CT
cannot be used, CXR and a high hematocrit especially in trauma patients are used to determine
the presence of hemothorax.

Figure 1. Massive hemothorax.
Hemothorax on the left lung. Blue arrow indicates presence of hemothorax. Image graciously provided by Drs.
Alan Cook and Scott Norwood of the University of Texas Health Science Center at Tyler.

Treatment of Hemothorax
Not all hemothoraces require treatment. However, current treatment options for the removal
of a hemothorax include tube thoracostomy, video-assisted thoracic surgery (VATS), and
thoracotomy. In some cases, prophylactic antibiotics may have been accompanied with invasive
treatment techniques, especially non-traumatic hemothorax to prevent further complications [3,
4, 19]. In the literature, it has been indicated that patients with a hemothorax less than 300 mL
are most likely to recover without invasive treatment or with thoracostomy alone [3, 6, 20].
4

However, hemothoraces of a greater volume often require more invasive treatment.
Thoracostomy drains pleural effusions through a tube that has been surgically inserted in the fifth
intercostal space [20]. According to the Advanced Trauma Life Support course produced by the
American College of Surgeons in 2018, a tube in the 28-32 French range should be utilized for
thoracostomy [21]. However, the literature also indicates that a larger tube size (36-40 French)
should be used in order to prevent clotted blood from creating a blockage in the tube resulting in
more successful draining [3, 22]. There is further controversy which indicates that French tube
size is based solely on preference of the attending physician rather than clinical significance [3].
Regardless, draining the pleural fluid has been indicated as the best first line of treatment for
hemothorax [7, 19].
Unfortunately, failure of tube thoracostomy occurs in as much as 30% of cases [16], and
complications have been reported in as high as 40% of cases [23, 24]. Complications of tube
thoracostomy can result from chest tube placement, removal, or infection, though the incidence
of these issues is highly variable and poorly reported [23]. Larger hemothoraces require surgical
consideration when the collection of patient’s blood in the pleural space becomes ≥1500 mL
within a 24 h period or increases by 200 mL per hour for several hours [3, 6]. In some cases, the
fluid begins to clot and create a clotted structure that can no longer be absorbed by the body or
drained through tube thoracostomy resulting in a retained hemothorax. Retained hemothorax can
lead to the need for other more invasive treatments including thoracotomy. Thoracotomy is a
highly invasive procedure in which the patient must undergo surgery to excise the retained
hemothorax. Due to the invasiveness of this procedure, thoracotomy is a last resort for the
removal of a retained hemothorax to prevent further complications including empyema. Thus, it
is vital that efficient and reliable techniques be used in place of thoracotomy.
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One technique which extracts a retained hemothorax through the use of VATS has been
increasingly replacing thoracotomy in recent years [18]. Stiles et al. even claims that VATS is
the most extensively accepted treatment of retained hemothorax [10]. This treatment uses an
endoscope to quickly excise a retained hemothorax with fewer complications resulting in a
decrease in morbidity and mortality associated with the technique [5, 8, 18]. Patients must be
hemodynamically stable which can be especially difficult for patients with penetrating or blunt
trauma [4, 5, 18, 19]. Unfortunately, blunt or penetrating traumatic injury is the largest cause of
retained hemothorax as mentioned leading to the reduced incidence of the technique [3].
Intrapleural Fibrinolytic Therapy
Another treatment option is the use of intrapleural fibrinolytic therapy (IPFT). Plasminogen
activators such as tissue-type plasminogen activator (tPA) and urokinase (uPA) are used for
IPFT to activate plasminogen (PLG) for fibrin degradation. tPA is a naturally occurring protein
present in circulation as a part of the endogenous fibrinolytic system while uPA is an
extracellular proteolytic enzyme [25]. Single-chain tPA is produced by endothelial cells in
humans and becomes activated to produce two-chain tPA, however, expression of sctPA has
been found in other cell types [26, 27]. Plasminogen activator uPA is also produced by
endothelial cells along with macrophages, renal cells, and some types of cancer cells [26-28].
Mature plasminogen is a 791-amino acid zymogen which contains kringle (looped) domains
that facilitate binding [26, 29]. Plasminogen is cleaved by plasminogen activators such as tPA
and uPA to produce the active form, plasmin (Figure 2) [26, 27]. Plasmin cleaves crosslinked
fibrin at C-terminal regions on the α and β chains within the D domain giving rise to D-dimer
degradation products [26]. Introducing exogenous tPA or uPA to the system facilitates
plasminogen activation. Plasminogen activators have been used for the treatment of different
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conditions including arterial thrombosis and failed thoracostomy for over 70 years with varying
degrees of success [19, 26, 27, 30, 31].
Plasminogen
activator

PAI-1
Plasmin

Plasminogen

Ca2+
Fibrin

Blood
Clot

α2 antiplasmin

Fibrinogen

Thrombin

Clot
Degradation
Products

Activated
Platelets

WBCs

RBCs

Figure 2. Blood coagulation and degradation.
When the coagulation pathway is stimulated in the blood, thrombin cleaves fibrinogen (in beige) to produce fibrin
(pink strands) which creates a blood clot along with red blood cells (RBCs), white blood cells (WBCs), and activated
platelets. Plasminogen activator (green) is produced and cleaves plasminogen (dark blue) resulting in the active
form, plasmin (light blue). Plasmin then cleaves the fibrin clot, producing degradation products.

The initial development of these fibrinolysins met set-backs due to low purity of the
substances. Once better purification methods were developed, the difficulty became proper
dosing requirements and administration parameters [32]. Unfortunately, these issues remain the
greatest concern with the use of plasminogen activators for treatment. While there have been
several case reports with fibrinolytics that have yielded promising results, there have not been
extensive clinical trials which could determine dosing parameters and possible side effects.
Another concern with this treatment is possible hemorrhagic complications. Several reports
including one by Lansberg et al. (2007) indicated cerebral hemorrhaging which occurred after
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the administration of tPA for the treatment of acute stroke [33]. This report and those like it
resulted in increased concern and apprehension with the use of fibrinolysins for thrombolytic and
fibrinolytic therapeutics. In combination with the absence of administration guidelines and the
reports of hemorrhaging, hesitancy and skepticism have hindered further research to standardize
these treatments. However, if fibrinolytics could be standardized, it is possible they might be a
replacement for some of the more invasive techniques including thoracotomy for the treatment of
retained hemothorax.
Preclinical Models of Hemothorax
The need for a highly effective, less surgically invasive treatment option for retained
hemothorax is significant. Unfortunately, although IPFT is far less invasive than other surgical
last resorts such as thoracotomy, the administration of plasminogen activators is still undefined.
Due to the inconsistent incidence and severity of retained hemothorax, studying possible
treatments in large patient cohorts is not currently possible. The possibility of hemorrhaging due
to fibrinolytic treatment contributes to the lack of patient studies. Historically, animal models
have been used to fill the need for studies of thoracic injury [34, 35]. Different models have been
implemented using a variety of animals including mice, rats, guinea pigs, and piglets [34, 35].
These varying projects establish the use of animal models in thoracic research [34-40].
Therefore, the use of an animal model is an appropriate method to study IPFT for the treatment
of retained hemothorax.
A rabbit hemothorax model is being developed to ascertain the development and progression
of retained hemothoraces. The model will be used to determine the effects of different
fibrinolytic therapies for the treatment of retained hemothorax. However, before IPFT treatment
is instituted in the rabbit hemothorax model, plasminogen activators must be studied in vitro to
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assess their effects on the induction of clot lysis. An assay that could be used to determine the
efficacy of plasminogen activators is crucial. We proposed a companion assay that would assist
in the study of IPFT in support of the rabbit hemothorax model. The basis of this assay had been
developed on the premise set by Bonnard and colleagues [41]. A whole blood thrombolysis plate
assay with human blood demonstrated that the formation of an artificial clot in the well of a 96well microtiter plate can be used to measure clot lysis [41]. Therefore, clots made from rabbit
blood, thrombin, and calcium were produced in 96-well plates and lysed by the addition of
human plasminogen activators tPA or uPA in solution to study fibrinolysis.
In this study, it was observed that the addition of tPA to artificial blood clots in solution
resulted in similar clot lysis in rabbit and human blood. However, there were some differences
observed between plasminogen activators used on rabbit blood clots. These differences indicated
a discrepancy in the human and rabbit fibrinolytic systems. The differences in the fibrinolytic
systems of rabbits and humans have previously been shown by several investigators. Studies
showed that plasminogen activation is generally similar in rabbit and human blood even though
the composition and concentration of the specific biochemicals is different [42, 43]. Identifying
differences of plasminogen activator activity in the rabbit and human systems using the assay
could be used in support of the model. Eliminating plasminogen activators that cannot be related
to humans would prevent the waste of resources. Determining the efficacy of applicable
plasminogen activators in the rabbit model could also aid in advancing the treatment of retained
hemothorax with IPFT.
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RESEARCH HYPOTHESIS
Standardized pharmacological treatment options for retained hemothoraces remain
unavailable at this time. However, the advantages of fibrinolytic therapy have been shown in the
literature. The hypothesis of this project was that a companion 96-well format assay could be
developed to effectively elucidate the formation and monitoring of hemothorax clot lysis, which
is instrumental for preclinical and clinical research, and could contribute to personalized therapy
of retained hemothorax. The objectives of this project were to (1) develop an in vitro 96-well
plate assay to monitor hemothorax clot lysis using plasminogen activators and exogenous human
plasminogen and (2) validate the assay using whole blood samples from the rabbit hemothorax
model.
Objective 1 was achieved by determining preparation parameters of the assay. How long
blood could be used, at what temperature blood needed to be stored, and understanding which
clotting mixture induced thrombolysis in whole blood samples were all determined. Clots were
formed in wells using whole blood samples and clotting mixtures. Different plasminogen
activators were added to wells in solution. Resulting fibrinolysis was observed through
spectrophotometry which monitored the increase in absorbance resulting from the release of
heme as the clot was lysed.
Objective 2 was accomplished by the collection of blood samples from the hemothorax rabbit
model. These samples were used to create the artificial clots at the bottom of 96-well microtiter
plates. Fibrinolysins including human tPA and uPA were added to the wells in solution. Whole
human blood (Zenbio) from healthy blood donors was also used to elucidate possible translation
of the assay in humans.
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MATERIALS AND METHODS
Hemothorax Rabbit Model
Animal protocols were approved by the IACUC standards committee at the University of
Texas Health Science Center at Tyler Health Science Center (UTT HSC, formerly UTHSCT) in
accordance with the “Standard Operating Procedures for Working with Rabbits at UTHSCT”.
New Zealand White, rabbits both male (n=9) and female (n=52) were used in this model.
Chest Tube Placement
The rabbits were anesthetized according to IACUC standards and the SOP for Working with
Rabbits at UTT HSC (Table 1) and monitored for wakefulness for 10-15 minutes after drug
administration either via intramuscular (IM) or subcutaneous (SC) injection. The skin over the
right thorax was shaved, and the sterile field was prepared using aseptic technique from the 4th
to the 12th rib. An introducer or feeding needle and catheter was inserted through the skin into
the pleural space before removing the introducer or needle to allow the chest tube to be inserted.
The chest tube was sutured in place, and the two-way valve was flushed with saline (NaCl +
water). The insertion site was covered with sterile gauze and protective wound covering. Chest
tube was flushed daily with saline (1-1.5 mL).

Table 1. Chest Tube Placement Anesthesia Protocol

Pre-anesthesia
Buprenorphine
IM
Midazolam IM

Induction

Dexmedetomidine IM

Local
Lidocaine SC
Bupivacaine
SC

Maintenance
Isoflurane (only
if needed)

Reversal
Atipamezole
IM
Flumazenil IV
or IM

Evaluation of Hemothorax by Ultrasound and Computed Tomography
After the insertion of the chest tube, the placement and positioning of the tube was verified
using CT. Seventy-two hours after the 3rd induction, the induced hemothorax was also
11

visualized using CT imaging. Following each induction, the presence of a hemothorax was
monitored by US using the GE Logiq E Ultrasound ™ System. Coronal and axial perspectives of
the right side were imaged. These US images allowed visualization of the hemothorax, chest
wall, heart, and lung without the need for anesthesia. Oxygen was administered when clinically
indicated by a low level of oxygen saturation in the animal.
Induction of Hemothorax
Once the chest tube was placed, rabbits received homogenous whole rabbit blood. Blood was
injected into the intrapleural space through the chest tube with 10 mM CaCl2 and thrombin (0.5
U/mL). This process was performed at 0, 24, and 96 hr at volumes of 30, 60, and 30 mL
respectively. Vital signs of the rabbits were also monitored at least every 10 minutes during and
immediately after each procedure and then twice a day. Buprenorphine was administered every
12 hours subcutaneously 3 times after the first induction.
Rabbit Endpoint Data Collection
Ultrasound and CT imaging were performed prior to euthanasia. Pentobarbital was
administered intravenously through the marginal vein of the ear at a dose greater than or equal to
100 mg/kg of the body weight to euthanize the animal. Death was confirmed with the cessation
of a heartbeat and absence of corneal reflex. Post-mortem examination was conducted to observe
the hemothorax and pleural space. The thorax of each rabbit was then surgically excised and
placed in 10% formalin solution for fixation and storage.
Non-survival Blood Collection in Rabbits
Rabbits were anesthetized according to IACUC approved standards according to the animal
model SOP. Rabbits were first administered midazolam (an anxiolytic) and buprenorphine (a
pain medication) intramuscularly. Rabbits were then administered dexmedetomidine (a sedative)
12

at least 10 minutes later (Table 2). Ketamine (a surgical anesthetic) was then given
intramuscularly to ensure rabbits were fully anesthetized (Table 2), and rabbits were monitored
to ensure complete anesthesia prior to continuing. Once anesthesia was confirmed, a 20 gauge
needle and syringe were used to puncture the left ventricle by inserting the needle below the
sternum to collect 100-140 mL of blood into pre-citrated syringes. In cases where the animal did
not expire from exsanguination, it was then euthanized using pentobarbital injected into the heart
(Table 2). In each case, the collected blood was refrigerated at 4°C while rocking to prevent
clotting and RBC lysis unless blood was to be immediately administered.

Table 2. Euthanasia Anesthesia Protocol

Pre-anesthesia
Buprenorphine
IM
Midazolam IM

Induction

Maintenance

Euthanasia

Dexmedetomidine IM

Ketamine IM

Euthanasia Soln.

Survival Blood Collection in Rabbits
Rabbits were sedated according to IACUC approved standards and the UTT HSC SOP.
Rabbits were first administered a depressant intramuscularly. Blood was then collected from the
marginal vein of the ear(s). No more than 2 mL of blood was collected each week as needed into
pre-citrated syringes. The blood was then collected into 2 mL tubes and stored under
refrigeration at 4°C with rocking to prevent clotting.
Lung Tissue Slide Preparation
After euthanasia, the thorax of each rabbit was removed and perfused for fixation in formalin
(10%) for at least 48 hours. Once fixed, the lower lobe of the injured lung was processed for
histology. Each sample was encased in paraffin (wax) blocks using a tissue processor in the
following solutions: 50%, 70%, 90%, 100% ethanol, and Clear-Rite 3 (xylene, Richard Allan
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Scientific). Slices of 5 µm thickness were cut from these blocks using a rotary microtome (Leica
Biosystems). These slices were then placed on Histobond adhesive slides (StatLab) using a water
bath heated to 37°C. Slides were then placed on a 60°C slide warmer until excess fluid was
evaporated from the tissues after which they were then cooled and stored at room temperature.
Hematoxylin and Eosin Staining
Hematoxylin and Eosin (HE) stains were used to identify structural changes in cell tissue
types and local cell structures as a result of the induced retained hemothorax. The nuclei of cells
stain a purple/blue color while the extracellular matrix and cytoplasm stain a pink color [44].
Focus was placed on changes in the pleural lining of the tissue as well as structural changes of
the alveolar spaces of the lungs. The slides were initially incubated at 60°C for 30 minutes to
melt the paraffin wax from the slides. The slides were then washed in Clear-Rite 3 (RichardAllan Scientific) for 30 minutes to clear the wax from the slides. The slides were subsequently
treated with the following solutions: 25 dips in 100, 90, 80, 70, and 50% ethanol, DI water for 25
dips, Hematoxylin for 3 minutes, DI water for 25 dips twice, 1% Acetic Acid for 1 minute, DI
water for 25 dips, Vintage Blue Solution for 30 seconds, DI water for 25 dips, 90% ethanol for
25 dips, Di water for 25 dips, Eosin for 30 seconds, and DI water for 25 dips twice. Slides were
then dehydrated by sequentially performing 25 dips in 50, 70, 80, 90, and 100% in ethanol.
Slides were then washed in Clear-Rite 3 (Richard-Allan Scientific) for 10 minutes and allowed to
dry before being mounted with 1-2 drops of Permount Mounting Fluid (Fisher Scientific). A
glass cover slip was placed over the sample and allowed to dry overnight. The slides were
imaged using Cytation 5 Cell Imaging Multi-Mode Reader (BioTek, Inc.).
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Masson Trichrome Staining
Masson Trichrome staining was used to ascertain the potential presence of collagen in the
pleural lining of the injured lung as a result of the induced retained hemothorax. The Masson
Trichrome Kit from Thermo Scientific was used to stain these tissue samples. The slides were
incubated at 60°C for 30 minutes to melt residual paraffin wax from preparation. The slides were
washed in Clear-Rite 3 (Fisher Scientific) for 10 minutes. Slides were then hydrated by
sequentially performing 25 dips in 100, 90, 80, 70, and 50% in ethanol. Slides were then treated
with the following solutions (Thermo Scientific): Bouin’s fluid at 60°C for 1 hour (Bouin’s fluid
was equilibrated in incubator before addition of slides), DI water for 50 dips twice, Working
Weigert’s Iron Hematoxylin Stain for 5 minutes, DI water for 50 dips twice, Scarlet-Acid
Fuchsin Solution for 5 minutes, DI water for 25 dips twice, Phosphotungstic-Phosphomolybdic
Acid Solution for 5 minutes, Aniline Blue Stain Solution for 10 minutes, DI water for 25 dips,
1% Acetic Acid Solution for 1 minute, and DI water for 25 dips. The slides were then dehydrated
by sequentially performing 25 dips in 50, 70, 80, 90, and 100% ethanol before being washed
with Clear-Rite 3 (xylene, Richard-Allan Scientific) for 10 minutes. Slides were allowed to dry
before being mounted with 1-2 drops of Permount Mounting Fluid (Fisher Scientific). A glass
cover slip was placed over each sample before being dried overnight. The slides were then then
stored at room temperature (25ºC). Slides were imaged using Cytation 5 Cell Imaging MultiMode Reader (BioTek, Inc.).
Development of Blood Halos in Well Format
Analyzing the Amidolytic Activity of Plasminogen Activators tPA and uPA
An amidolytic assay was used to analyze the activities of tPA and uPA to measure their
ability to activate PLG using solutions of 10.7 µM uPA, 10.4 µM tPA, and 11.6 µM PAI-I were
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prepared in reaction buffer (20 mM HEPES, 130 mM NaCl, and 1mg/mL BSA). The
plasminogen activators tPA and uPA were prepared at 1x and 2x molar concentrations both
separately and with PAI-1. Plasminogen activator inhibitor is an inhibitor was used to
differentiate the activity and inhibition of the plasminogen activators. In a black, flat-bottom 96well plate, 98 µL of reaction buffer was pipetted into samples wells. 2 µL of sample was added
to the wells for a total volume of 100 µL. The solution was mixed and serially diluted using a
multichannel pipettor. Pefafluor tPA (Pentapharm) was added to the plate before reading.
Fluorescence was measured using an excitation wavelength of 350 nm and an emission
wavelength of 450 nm using the Synergy H1 hybrid Multi-mode Microplate reader or the
Cytation 5 imaging reader (BioTek, Inc.). The rate of the change in relative fluorescence units
(RFU) was measured over time and analyzed using compatible Gen 5 software (BioTek Inc.).
Analyzing the Plasminogen Activation of Fibrinolysins tPA and uPA
In order to assess the activation of PLG by tPA and uPA, a plasminogen activation assay was
performed. This was used to determine how well PLG was activated into plasmin by
plasminogen activator. Stock solutions of 10.4 µM uPA, 10.7 µM tPA, and 11.6 µM PAI-I were
prepared in reaction buffer (20 mM HEPES, 130 mM NaCl, and 1mg/mL BSA). Plasminogen
activator samples were prepared separately at 1x and in excess with PAI-1. Samples were also
prepared containing each enzyme alone. A clear flat-bottom 96-well plate was used for this
experiment. 95 µL of reaction buffer (20 mM HEPES, 130 mM NaCl, and 1mg/mL BSA) was
pipetted into sample wells. PLG (100 nM) was added to the plate. 200 µL of Pefachrome PL
(Pentapharm) was then also added to the plate (~2 µL per well). The change in OD405 was
measured using Synergy H1 hybrid Multi-mode Microplate reader or Cytation 5 imaging reader
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(BioTek, Inc.). The rate of change was calculated using the compatible Gen 5 software (BioTek
Inc.).
Analyzing Activity of Plasminogen Activators tPA and uPA Using SDS PAGE
To confirm activities of plasminogen activators tPA (70 kD) and uPA (54 kD), an SDS-PAGE
gel was performed. Working solutions of 10.7 µM uPA, 10.4 µM tPA, and 11.6 µM PAI-I (43
kD) were prepared in reaction buffer (20 mM HEPES and 130 mM NaCl, and 1 mg/mL BSA).
Samples were prepared at 1x and in excess of enzyme and inhibitor in reaction buffer with a total
volume of 20 µL per sample. Samples were also prepared with tPA, uPA, and PAI-1 alone. 5 µL
of loading buffer (NuPAGE LDS Sample Buffer 4x, Invitrogen) was added to each sample. All
samples were heated for 2 minutes at 95°C. Reaction mixtures were resolved using NuPAGE
Novex 4-12% Bis-Tris Midi gels (Invitrogen). Gel was stained in 20 mL of Gel Code Blue Safe
Protein Stain (Thermo Fisher). The gel was incubated while rocking at room temperature for 1
hour. The gel was de-stained with MilliQ water until water washed clear. The gel was imaged
using the Bio-Rad ChemiDoc MP System. Volumetry was also performed on the gel using
BioRad Image Lab Software Volumetry Tool.
Measuring the Effects of Blood Halo Volume on Optical Density (OD)
The blood volume in each well to create a halo was 25 µL according to Bonnard et al. To
determine what volume of rabbit blood would be suitable for the application of this assay,
several blood volumes were added to separate wells of a clear, flat-bottom 96-well plate (CoStar,
Fisher Scientific). Blood volumes of 1, 2, 4, 5, 8, 10, 12, 15, 18, 20, and 25 µL were added to in
HEPES buffer plus BSA (20 mM HEPES, 137 mM NaCl, 1 mg/mL BSA) for a total volume of
100 µL. These samples were prepared in duplicates. The plate was read on Synergy H1 hybrid
Multi-mode Microplate reader (BioTek Inc.) at 510 nm.
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Development of Blood Halos
A clotting mixture was first prepared for creation of blood halos. If a human whole blood
sample was used, Dade Innovin (recombinant human tissue factor combined with synthetic
phospholipids, and calcium) and calcium chloride (67 mM) in HEPES buffer plus BSA (25 mM
HEPES, 137mM NaCl, 1 mg/mL BSA) solution was prepared. If a rabbit whole blood sample
was used, thrombin (0.01 U/µL per well) and calcium chloride (67 mM) in HEPES buffer plus
BSA (20 mM HEPES, 137 mM NaCl, 1 mg/mL BSA) solution was prepared. 2 µL of the
clotting mixture was plated into the bottom edge of a well of a clear, flat-bottom 96-well plate
(CoStar, Fisher Scientific). 10 µL of blood collected in EDTA or sodium citrate was deposited
into the bottom of the well and spread in a circular motion around the outer edge of the well in
order to thoroughly mix the solution. The plate was sealed and incubated at 37°C for 30 minutes
before being stored at 4°C.
Assessing Clot Lysis Using tPA and uPA to Induce Plasminogen Activation
After confirmation of tPA and uPA, these enzymes were then used in the blood halo assay to
determine how these plasminogen activators might induce clot lysis through the activation of
PLG to plasmin in rabbit blood. The clot lysis in rabbit blood was compared to that in human
blood samples obtained from zenbio. Fibrinolysis was measured with different concentrations of
human PLG (29, 14.5, 6.25, and 0 nM, (Haematologic Technologies) and either two chain
urokinase (uPA, 5 nM, Molecular Innovations) or two chain tissue plasminogen activator (tPA, 5
nM, Molecular Innovations) in each well. The total final volume of reaction mixture in each well
was 100 µL. Control wells contained triplicates of 29, 14,5, 6.25, and 0 nM PLG in reaction
buffer (20 mM HEPES, 130 mM NaCl, and 1mg/mL BSA). The plates were immediately read
after the addition of a plasminogen activator and measured for change in absorbance at 510 nm
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on Synergy H1 hybrid Multi-mode Microplate reader or the Cytation 5 imaging reader (BioTek
Inc.). The changes in absorbance were monitored for a minimum of two hours at 37°C. The rate
of fibrinolysis was then calculated using Cytation 5 software (BioTek Inc.) and GraphPad Prism.
The experiment was repeated as needed using tPA or uPA in a single plate.
Determining the Effect of Exogenous Human Plasminogen on Blood Halos
The above protocol as above was used to analyze the effect of exogenous human PLG alone
(Haematologic Technologies) to the system as well. The effect of endogenous human PLG (29,
14.5, and 7.25 nM) on the reaction was measured to determine the significance if any in the
addition of human PLG to the system in rabbit and human blood halos. GraphPad Prism was
used to assess differences in PLG.
Optimization of Blood Halo Assay Using I.DOT Dispensing Tool
The preparation of blood halos was performed using the I.DOT to determine if this process
could also be automated to reduce preparation time. The I.DOT was used to distribute 10 µL of
whole blood over 2 µL of thrombin (0.01 U/µL) droplets. The blood halo plate was then sealed
with a foil seal to prevent humidity loss. Plates were then incubated in a CO2 incubator (5%)
overnight at 37°C before being placed at 4°C. The plates were tested using manual pipetting of
PLG (29, 14.5, and 7.25 nM) and plasminogen activators (5 nM). Control wells received buffer
only. The plates were read using Synergy H1 hybrid Multi-mode Microplate reader (BioTek
Inc.) at 510 nm.
Statistical Analysis
Statistical analysis using Tukey’s multiple comparisons test was accomplished using
GraphPad Prism to compare independent groups of data using degrees of freedom. Unpaired ttests were also used to analyze independent groups of data using GraphPad Prism.
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RESULTS
Induced Hemothorax Model in Rabbits
The hemothorax model was developed in rabbits to elucidate the progression of hemothoraces
to retained hemothoraces over a 7-day period. Blood was collected for the induction of retained
hemothoraces by the non-survival blood collection protocol as described in the methods.
Coagulation was prevented in the collected blood using a 4% w/v sodium citrate solution. A
chest tube was placed in the pleural space on the right side of all experimental rabbits. The
position of the chest tube was confirmed by computed tomography and ultrasonography. The
model timeline began with chest tube placement as described in the methods (Figure 3). In initial
development, only a single induction of homologous blood was introduced to the pleural space.
This single induction did result in a hemothorax. At the conclusion of the initial experiments,
post-mortem examination indicated that a retained hemothorax was formed. However, the
retained hemothorax was not as pronounced. In order to imitate continuous bleeding, which
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NOTE: Injected blood has been recalcified and contains thrombin due to citrate used at
donor blood collection to keep from clotting.

Figure 3. Hemothorax Model.
Rabbit hemothorax experiment timeline. Blood was collected from the donor rabbit group and citrated as
chest tubes are placed in the experimental rabbit group. Blood was then recalcified in the presence of
thrombin (0.5 U/mL) and injected through the chest tubes of the experimental rabbit groups at 0, 24, and 96
hours. The blood in the pleural space was confirmed through computed tomography (CT) and ultrasound
(US) imaging. At the end of the experiment, all rabbits were euthanized for gross analysis.
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occurs especially with traumatic hemothoraces, the next iteration of the model used three total
inductions of 60, 30, and 30 mL respectively. Animals struggled to recover with a large initial
volume of blood introduced to the pleural space. In order to alleviate some of the stress on the
animal, the volume of blood was lowered for the first induction and raised for the second. This
resulted in better support of the animal’s wellbeing. Thus, three blood injections through the
chest tube at 0, 24, and 72 hours using blood volumes of 30, 60, and 30 mL respectively were
used (Figure 3). The blood was administered with thrombin (0.05 U/mL) in the presence of
calcium chloride (10 mM) to induce clotting.
The resulting hemothorax was monitored by ultrasonography after each induction and then
before takedown. The chest tube was flushed with saline each day to clear blood from the tube
which could potentially cause a blockage. The results of ultrasonography showed depression of
the lungs and heart in the presence of a hemothorax (Figure 4). The progression of the
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Figure 4. Ultrasound Images of Blood Inductions in Rabbits.
Chest ultrasounds showing pre and post inductions at 0, 24, 96, hr and before takedown at 168 hr. (Panel A) Clot
seen adjacent to lung (L) and heart (H). (Panel B) Clot seen adjacent to lung (L) and heart (H). (Panel C) Clot causing
compression of the heart (H) and atelectatic lung (L). (Panel D) Clot causing compression of the heart (H). (Panel
E) Clot causing compression of the heart (H). (Panel F) Clot seen adjacent to the chest wall (CW) and compressing
the lung (L) and heart (H).
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hemothorax was associated with adherence of the clot to the chest wall, lung, and/or
pericardium. The US also showed retained structures of clot that appeared along the chest wall
(Figure 4).
Upon conclusion of the experiment, the experimental rabbit group was euthanized. A postmortem examination was conducted at the end of the experiment. Incisions were made on the
right and left side of the sternum across the ribs which opened the chest cavity and pleural space.
Gross images were taken of any visible tissue structures including the retained hemothorax,
strands, and/or webbed mesh using a FujiFilm X100V digital camera. Gross images showed the
presence of clot attached to the chest wall and pericardium (Figure 5). Several fibral adhesions
could also be seen attaching a clot to the chest wall (Figure 4). A webbed mesh of strands was
also observed in one animal which attached the clot to the lung, chest wall, and diaphragm
(Figure 5). It was also noted that the left lungs were typically uninvolved.

Figure 5. Gross imaging of retained hemothorax in rabbits.
Once rabbits were euthanized, post-mortem examination was conducted immediately. The chest was opened on the right and
left side of the sternum to access the pleural space. Landmark structures including the heart (H) and chest wall (CW) were
used to locate the position of clots, strands, or mesh (Panels A, B, C). (Panel A) The heart surrounded by the pericardium and
a large clot that was attached to the chest wall. (Panel B) Strands attached to a clot and the chest wall. (Panel C) Mesh attached
to a clot and the chest wall.
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The chest cavity was excised from the thorax of each rabbit and fixed in formalin according to
the procedure in the methods before sections of the lower lobe of the right lung were used for
histological examination. The lung sections were subjected to H&E and Trichrome staining.
Histological examination using H&E showed pleural thickening and pneumonitis (Figure 6).
Trichrome staining indicated the presence of collagen deposition along the lining of the lung
(Figure 6) accompanied by thickening of the alveolar walls and pleura. Both stains also showed
reduced volume of the alveolar spaces indicating a reduction in pleural function. The pleural
injuries shown by these histological techniques indicate that the induction of a retained
hemothorax was successful. The presence of these injuries showed how retained hemothoraces
affect lung morphology. Imaging techniques, gross presentation, and histology examinations
indicated that hemothoraces were induced in rabbits.

Figure 6. H&E and Trichrome Staining.
Sections of lung were fixed in formalin, suspended in paraffin wax, and cut into 5 µm thick sections for histology
staining. The sections were subjected to H&E (Panels A and B) and Trichrome (Panels C and D) staining. Images
were obtained at 4X (Panels A and C) and 20X (Panels B and D) using Cytation 5 (BioTek, Inc.). Pleural thickening
(red arrows) and collagen deposition (blue arrows) were apparent in the injured lung sections. Alveolar spaces appear
reduced compared to healthy lung indicating reduction of pleural function.
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Amidolytic Assay
tPA and uPA are the two main plasminogen activators used in IPFT [25]. Therefore, these
plasminogen activators were chosen to be used for the development of the blood halo plate assay.
An amidolytic assay was used to detect the activity of tPA and uPA using the fluorogenic
substrate Pefafluor tPA (Pentapharm). Pefafluor tPA (Pentapharm) is lysed by tPA or uPA,
freeing the fluorophore which changes the relative fluorescence of the solution. The resulting
change in relative fluorescence (350/450 nm) over time measured to determine the relative
activity of the plasminogen activator alone or in the presence of PAI-1 (Figure 7, Panels A and
B). In this experiment, an increase in the relative rate of the fluorescence change in the sample
was observed with an increase in the concentration of tPA or uPA (Figure 7). Wells containing
PAI-1 with tPA or uPA resulted in much lower relative fluorescence changes if at all (Figure 7)
due to irreversible mechanism-based inhibition by the serpin, suggesting that these enzymes
were active in the absence of PAI-1.
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Figure 7. Measuring amidolytic activity of plasminogen activators tPA and uPA.
To ensure tPA and uPA were active, an amidolytic activation assay was used. Activities of tPA (10.4 µM) and uPA (10.7 µM)
were measured in the presence and absence of PAI-1 (11.6 µM) using fluorogenic substrate Pefafluor tPA. Change in RFU/min
measured for excitation at 350 nm and emission at 450 nm. tPA (orange) and tPA in 2X molar excess (blue) showed similar
activity which was reduced in the presence of PAI-1 (black and red) and PAI-1 in 2X molar excess (green). The reduction of
activity in the presence of PAI-1 suggests tPA was active in the absence of PAI-1. (Panel B) uPA (orange) and uPA in 2X
molar excess (blue) appeared to have greater activity than uPA in 2X molar excess in the presence of PAI-1. Activity was
reduced with uPA and PAI-1 (black) and PAI-1 in 2X molar excess (green) suggesting the enzyme is active in the absence of
PAI-1.
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Plasminogen Activation Activity Assay
A PLG activation activity assay is a chromogenic assay which measures the change in the
OD405 over time. This experiment was used to detect the activation of PLG to plasmin by the
plasminogen activators tPA and uPA. The PLG activation was detected using Pefachrome PL
(Pentapharm), a chromogenic plasmin substrate. The activation of PLG to plasmin by the tPA or
uPA was monitored by accumulation of the product of cleavage of Pefachrome PL (Pentapharm)
resulting in an increase in OD of the solution. An increase in the production of plasmin was
observed as an increase in the OD405 in the reaction mixture (0.1 mL) which contained 0-6 nM of
plasminogen activators (Figure 8). Wells, with reaction mixture, contained PAI-1 and
plasminogen activator resulted in much lower rates of increasing of OD405 comparatively to
those that received plasminogen activator only (Figure 8, Panels A and B). Complete inactivation
with PAI-1 (Figure 8) confirms that both tPA and uPA have no active impurities.
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Figure 8. Measuring activity of plasminogen activators tPA and uPA
Activation of plasminogen by tPA (10.4 µM) and uPA (10.7 µM) was measured in the presence and absence of PAI-1 (11.6
µM) using Pefachrome PL as the substrate. The change in absorbance was measured in OD405/min. tPA (orange) and tPA in
2X molar excess (blue) showed similar activity (Panel A). tPA in 2X molar excess with PAI-1 (red) showed reduction in
activity. tPA in the presence of PAI-1 (black) and 2X molar excess PAI-1 (green) show that tPA was considerably inhibited
by PAI-1 suggesting that tPA was active in the absence of PAI-1. (Panel B) uPA (orange) and uPA in excess (blue) appeared
to have greater activity than uPA in 2X molar excess in the presence of PAI-1. Activity was further reduced with uPA and
PAI-1 (black) and PAI-1 in 2X molar excess (green) suggesting the enzyme is active in the absence of PAI-1.
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Visualization Distribution Between Active and Inactive of tPA and uPA
In order to further confirm the activity of tPA and uPA before use in the blood halo assay, the
distribution between active and inactive enzymes was visualized by the reaction with PAI-1
followed by SDS-PAGE (Figure 9).

Figure 9. Measuring plasminogen activator activity using SDS-PAGE.
tPA (10.4 µM) and uPA (10.6 µM) activity was assessed in the presence and absence of PAI-1 (11.6 µM) using SDS-PAGE
gel electrophoresis. Lanes 1-3 contained uPA and PAI-1, uPA in 2X molar excess and PAI-1 and uPA and PAI-1 in 2X molar
excess respectively. Lanes 4-6 contained tPA and PAI-1, tPA in 2X molar excess and PAI-1, and tPA and PAI-1 in 2X molar
excess. Lanes 7 and 8 contained uPA and uPA in 2X molar excess. Lanes 9 and 10 contained tPA and tPA in 2X molar excess.
Lanes 11 and 12 contained PAI-1. The yellow asterisk indicates ladder (250 kD). tPA (70 kD) and uPA (54 kD) were
complexed with PAI-1 (43 kD) at higher molecular weights than tPA and uPA alone suggesting the complexed portion of
enzyme was active.

Only active enzymes interact with PAI-1 forming an acyl-enzyme complex, which migrates at
100-110 kDa. tPA (10.4 µM) and uPA (10.7 µM) were incubated with 2x excess of PAI-1,
reaction mixtures were subjected to SDS-PAGE (Figure 9; lanes 3 and 6), stained with Gel Code
(Figure 9) and bands intensities were estimated as outlined in the methods. Pure enzymes and
PAI-1 (Figure 9; lanes 7-12) and their mixtures in ratios 1:1 and 2:1 (Figure 9; lanes 1-6) were
used as controls. Samples of tPA and uPA were used in the presence and absence of PAI-1. The
gel indicated that active enzyme was complexed with PAI-1. This is apparent by the comparison
of wells which contain plasminogen activator alone to those containing plasminogen activator
with PAI-1. The bands of complexed enzymes have higher molecular weights than those of the
enzymes alone (Figure 9). The stain was used to determine the fraction of active tPA or uPA
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through binding with PAI-1, and inactive enzymes (those that do not react with PAI-1). Intensity
measurements of the bands indicated that uPA was 68% active, tPA was 69% active, and PAI-1
was 75% active.
Determining Optimal Blood Volume for Halo Formation
The development of the assay was designed to determine what preparation parameters of
blood halos were appropriate for use with rabbit blood. Clot volume was determined by defining
the absorbance of whole blood in buffer to mimic the max absorbance resulting from complete
clot lysis. Whole rabbit blood was added to a 96-well plate in varying volumes to determine what
clot volume could yield measurable clot lysis. Each solution was mixed before the absorbance
was measured. The well which contained the highest volume of whole blood (25 µL) was
considered too high to be read by the spectrophotometer for which an absorbance value of 4 was
given which indicates a transmittance of 0.01% (essentially zero). Absorbance values decreased
as the total blood volume decreased, and the transmittance of light was decreased when the total
blood volume was increased (Figure 10). Volumes of blood ranging from 1-8 µL resulted in
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Figure 10. Blood halo volume effects maximum absorbance values.
Absorbance values were measured for blood volumes 1-25 µL. Blood was diluted in reaction buffer for a total volume of 100
µL. OD values increased with the increase in blood volume. Transmittance decreased as the blood volume increased.
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absorbance values within the optimal detectable range of less than 2. Volumes 10-25 µL resulted
in absorbance values greater than 2 and transmittance of less than 1%. Full blood halos created
from less than 10 µL of blood resulted in incomplete blood rings.
Comparison of Two Clotting Mixtures for Halo Formation
The reproducible generation of blood halo clots using whole blood samples and coagulation
factors was crucial for development of the assay. Determination of the appropriate coagulant of
rabbit blood, which was citrated upon collection, was conducted by preparing whole blood halos
with either thrombin or Dade Innovin. The halo clots formed were incubated with either 5 nM
tPa alone or with tPA in combination with PLG (29 nM) and rates of accumulation of OD510
were measured (Figure 11). Negative controls were halo wells containing either buffer only or
plasminogen and buffer (Figure 11). The rates of fibrinolysis for each set of experiments were
calculated and presented in boxplots (Figure 11). Upon measurement of fibrinolysis, wells
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Figure 11. The effect of different clotting factors on clot stability and lysis.
Measuring the stability and reproducibility of blood halo clot lysis in halos made with different clotting factors. Blood was
clotted with 2 µL of thrombin (0.01 U/µL) or Dade Innovin and CaCl2 (67 mM) in rabbit blood halos. The blood halos were
lysed using PLG activation by tPA (5 nM). Bars indicate range of values. Descriptive statistics resulted in coefficient of
variations of 42.91 (buffer), 52.50 (PLG 29 nM), 56.26 (tPA 5 nM), and 52.90 % (PLG 29 nM + tPA 5 nM) for rabbit blood
clots made with thrombin. Rabbit blood clots made with Dade Innovin resulted in coefficients of variation of were 48.81
(buffer), 45.04 (PLG 29 nM), 148.0 (tPA 5 nM), and 114.7 % (PLG 29 nM + tPA 5 nM). Descriptive statistics indicated
thrombin was a better coagulant for the formation of rabbit blood halos.
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containing halos prepared with thrombin were lysed more consistently (similar rates of
accumulation of OD510, Figure 11A) than blood halos made with Innovin (Figure 11B). One
outlier (ROUT (Q = 1%)) was identified in the Innovin group of a well lysed with tPA.
Descriptive statistics were used to determine the coefficients of variation between wells with
buffer alone, plasminogen, tPA, and tPA + plasminogen. The coefficients of variation for the
halos prepared with thrombin were 42.91, 52.50, 56.26, and 52.90 % respectively. The
coefficients of variation for halos prepared with Innovin were 48.81, 45.04, 148.0, and 114.7%
respectively.
Assessing Stability and Reproducibility of Blood Halos Over Time
Preliminary studies (not shown) indicated that blood halos could not be used immediately
after preparation due to a instability of the freshly formed clot. Thus, a minimal 24 h period was
determined a suitable halo-clot formation time, which is necessary for stable reproducible results
from the assay. However, it was unknown how long beyond 24 h plates could be used once
prepared. The stability of blood halos over time was evaluated by simultaneously preparing a set
of 5 plates using the same protocol as described in the methods and storing at +4°C. One out of 5
plates was used for measuring rates of fibrinolysis using either 5 nM tPA alone or in combination
with 29 nM PLG (Figure 12). Control experiments included incubation with buffer alone or in
combination with PLG (29 nM). The rates of fibrinolysis in each plate were determined using
either the Synergy H1 hybrid Multi-mode Microplate reader or the Cytation 5 imaging reader
(BioTek, Inc.). Each plate was read for at least 1.5 hours. The average rate of clot lysis was
calculated for each set of samples and presented as a boxplot (Figure 12). The results (Figure 12)
demonstrate high stability and reproducibility of the halo clots for up to 6 days. While the
average rate of clot lysis did not appear to change greatly across the five plates which were used
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in this experiment, a trend towards a decrease in the rates of fibrinolysis was detected at Day 7
(Figure 12).
Stability of Rabbit Blood Halos Over Time
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Figure 12. Stability of rabbit blood halos over time.
Blood clots made from rabbit blood were prepared on several plates using thrombin (0.01 U/µL) and CaCl2 (67 mM). Plates
were lysed with PLG activation induced by the addition of tPA (5 nM). The mean rate of clot lysis was measured for all five
plates. Triangles represent mean clot lysis of blood halos administered tPA and PLG (29 nM). Squares represent blood halos
which received PLG (29 nM), and circles represent halos which received buffer alone. The mean rate of clot lysis did not
appear to change greatly over the five plates measured 3-7 days after preparation indicating that plates can be used after several
days and do not need to be used immediately.

The Effect of Exogenous Human Plasminogen on Rate of Fibrinolysis of Halo Clots
Halo clot lysis was induced by tPA and uPA through the activation of endogenous
plasminogen that is incorporated in the clot. Therefore, plasminogen (endogenous or exogenous)
is required for halo clot lysis to occur. The amount of endogenous plasminogen available in the
whole blood clots was unknown. Therefore, in order to determine the effect of PLG on the rate
of fibrinolysis, exogenous human plasminogen (0-29 nM) was added to the wells with performed
rabbit and human halos. Rates of clot lysis were measured using the Synergy H1 hybrid Multimode Microplate reader or the Cytation 5 imaging reader (BioTek Inc.). Tukey’s HSD test for
multiple comparisons showed that values between groups that received 29, 14.5, or 7.25 nM
concentrations of PLG were not significantly different from each other (p = 0.9325, p = 0.1303,
p = 0.3743) in rabbit blood (Figure 13). Wells which received 29, 14.5 and 7.25 nM PLG were
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also not significantly different from wells which received buffer only (p = 0.2038, p = 0.5088, p
= 0.9957). The wells which received 29, 14.5 or 7.25 nM PLG were not significantly different
than those that contained buffer alone (p = 0.2038, p = 0.5088, p = 0.9957) in rabbit blood.
However, in human blood, wells that received buffer alone were significantly different than
wells that received 14.5 nM PLG (p=0.0004, 95% C.I. = 0.01407 to 0.05776) and 29 nM
(p=0.0001, 95% C.I. = 0.01974 to 0.06343) (Figure 13). However, wells which received buffer
alone compared to those which received 7.25 nM PLG showed no significant difference (p =
0.0501) in human blood. Additionally, wells that received 29, 14.5, 7.25 nM were not
significantly different from each other (p = 0.8994, p = 0.0892, p = 0.3251) in human blood. The
results (Figure 13) indicate that while the rate of fibrinolysis of rabbit clots does not depend on
exogenous PLG (Figure 13A), it increases to saturating values upon an increase of the exogenous
PLG from 0 to 14.5 nM (Figure 13B).

Effect of Plasminogen on Human Blood Clots
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Figure 13. Measuring the effect of exogenous plasminogen on blood halos.
Exogenous PLG (29, 14.5, 7.25, and 0 nM) was administered to blood halos to determine if the addition of PLG had an effect.
Tukey’s HSD test for multiple comparisons showed that wells receiving PLG did not significantly differ from wells that
received buffer only (p = 0.2038, p = 0.5088, p = 0.9957) for rabbit blood halos (n = 60). Tukey’s HSD test for multiple
comparisons showed that wells receiving 29 nM (p=0.0001, 95% C.I. = 0.01974 to 0.06343) and 14.5 nM (p=0.0004, 95%
C.I. = 0.01407 to 0.05776) plasminogen were significantly different than those that received buffer alone (n = 48) indicating
that the addition of exogenous PLG had an effect on human blood halos but not rabbit blood halos.
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tPA and uPA Induce Fibrinolysis of Halo Clots Differently
The use of fibrinolytic therapy in humans has been under investigation for several decades
without defined efficacy or treatment standards [30, 31]. tPA and uPA have been shown to
induce fibrinolysis of thromboses in humans [9]. The effects of tPA and uPA (alone or in the
presence of exogenous PLG; 0-29 nM) on rates of fibrinolysis of halo clots were studied using
rabbit and human whole blood samples (Figure 14). Negative controls were wells which were
administered buffer only or buffer and PLG. Experimental wells received PLG and tPA or uPA.
A two-tailed unpaired t-test indicated that wells which contained tPA appeared to have a mean
greater activity (M = 1.915) than wells containing uPA (M = 0.1876; t(df) = 3.571, p = 0.0118)
in rabbit whole blood (Figure 14). However, in human whole blood, there was not a significant
difference between wells which were lysed with the addition of tPA (M = 2.800) compared to
wells lysed with the addition of uPA (M = 2.244; t(df) = 0.5735, p = 0.5872) (Figure 14).
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Clot Lysis Using tPA or uPA to Activate PA in Rabbit Blood
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Clot Lysis Using tPA or uPA to Activate PA in Human Blood
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Figure 14. Differences in clot lysis induced by tPA and uPA.
Clot lysis induced by the activation of plasminogen using tPA and uPA was measured in rabbit blood and compared to that in
human blood. Blood halos received tPA (5 nM) or uPA (5) with plasminogen (29, 14.5, 7.25, and 0 nM) in buffer. Statistical
analysis using a two-tailed unpaired t-test showed there was a significant difference between wells that received tPA and wells
that received uPA (M = 1.915, M = 0.1876; t(df) = 3.571, p = 0.0118) in rabbit blood (n = 68). A two-tailed t-test indicated
that there was no significant difference between wells that received tPA and wells that received uPA (M = 2.800, M = 2.244;
t(df) = 0.5735, p = 0.5872) in human blood suggesting that uPA acts differently in rabbit blood.

Notably, both human and rabbit blood halos receiving uPA were lysed slower than those with
tPA (Figure 15). In rabbit blood, clots receiving uPA were lysed approximately an hour later
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than those which received tPA (Figure 15). Human blood clots which received uPA were also
lysed later than those that received tPA, but this time difference was much shorter than that
observed with rabbit blood halos.

OD510

A

Time (hours)

OD510

B

Time (hours)
Figure 15. Time differences of plasminogen fibrinolysis induced by tPA and uPA.
Clot lysis occurred at different time points for tPA and uPA in rabbit (Panel A) and human blood (Panel B). Red trace was
well that received tPA (Panels A and B). Green trace represents well that received uPA (Panel A and B) showing that wells
which received uPA lysed later than those with tPA. Wells which received uPA were lysed significantly later in wells made
with rabbit blood (Panel A). Data are representative.

Optimizing the Blood Halo Assay Using I.DOT (Cellink)
Blood halos which were made using the I.DOT appeared to have similar fibrinolytic
activation as seen with manually pipetted blood halos (Figure 16). Statistical analysis using an
unpaired two-tailed t-test revealed there was statistical significance between wells which
contained tPA (M = 0.1848) and wells that did not contain tPA (M = 0.0070; t(df) = 4.238, p =
0.0055) in blood halos made from rabbit blood. A similar trend was observed in human blood
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halos made with the I.DOT which showed that there was a significant difference between halos
which contained tPA (M = 1.920) and those that did not (M = 0.0045; t(df) = 4.894, p = 0.0027).
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Figure 16. Optimization of blood halos using the I.DOT.
Blood halos were made using the I.DOT dispensing machine by CellLink. Blood halos were made with 2 µL of thrombin
(0.01 U/µL and CaCl2 (67 mM) and 10 µL of either rabbit or human blood. Blood halos were lysed by the activation of
plasminogen using tPA (5 nM). Blood halos appeared to lyse similarly in rabbit blood (Panel A) and human blood (Panel
B). Statistical analysis showed that wells which received tPA (M = 0.1848) and wells that received uPA (M = 0.0070; t(df)
= 4.238, p = 0.0055) were significantly different in rabbit blood (n=24). Human blood halos (n=24) also showed significant
difference in wells with tPA (M = 1.920) and uPA (M = 0.0045; t(df) = 4.894, p = 0.0027) indicating that the I.DOT can be
used for the formation of blood halos.
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DISCUSSION
Retained hemothorax is a pleural injury that affects hundreds of thousands of people each
year which can lead to further complications such as empyema and death [3]. Treatment options
for retained hemothorax that avoid invasive surgical intervention remain elusive. However, IPFT
might be the solution for treatment of retained hemothoraces if current limitations of this
treatment could be addressed. The use of a rabbit model could fill the need for a comparison of
fibrinolytic therapies in vivo. Furthermore, the plate model could be used to obtain beneficial
information that associates in vivo observation of fibrinolysis in rabbits with the human
condition. This rabbit model of retained hemothorax is an extension of the established practice of
animal research which studies the dynamic molecular interactions present in whole organisms
unavailable in in vitro models [34, 35].
In the rabbit model of retained hemothorax, the clinical indication of retained hemothoraces is
evident on US images through the depression of the heart and atelectatic lung accompanied by
attachment of the clot to the chest wall (Figure 4). Ultrasound analysis showed a clot between the
chest wall and the major organs that appeared to adhere to the chest wall over time (Figure 4).
Thus, the induction of 120 mL whole blood introduced in three total injections over 96 hours
resulted in a visible retained hemothorax. The presence of retained hemothoraces was confirmed
through post-mortem examination. The manifestation of a clot accompanied by mesh and/or
strand structures attaching clots to the chest wall indicated the presence of fibrin were also
observed post-mortem (Figure 5). Thickening of the visceral pleura along with collagen
deposition in the pleural lining were also observed through H&E and Trichrome staining (Figure
6). The pleural injury observations of this rabbit model demonstrated the translational benefit
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which potentiates the applicability of the animal model for the study of hemothorax and retained
hemothorax in humans.
The rabbit model of retained hemothorax accurately recapitulates the physical injuries of a
retained hemothorax. Therefore, the model can be used to assess treatment options of retained
hemothoraces using IPFT. The blood halo plate assay could be used to assess the fibrinolytic
activity of plasminogen activators before being used in the model. The blood halo assay which
was originally proposed by Bonnard et. al indicated the possibility of real time observation of
fibrinolysis of whole blood clots through the use of spectrophotometric analysis [41]. This blood
halo assay was adapted for use with whole rabbit blood to study the potential effects of
plasminogen activators prior to and accompanied with use in rabbits. Our blood halo assay
allows for in vitro testing to elect treatment options that have the greatest clinical significance
and efficacy in our animal model. The application of this assay in support of the model is
reinforced by the dogma of animal research which is to use as few animals as possible [34, 45].
Eliminating possible ineffective treatments before use in the model could potentially reduce the
quantity of animals needed to elucidate proper treatment options. The blood halo assay could
also assist in the measurement of inadequate or ineffective dosing parameters which would
further assist in the understanding and use of IPFT.
The plasminogen activators used for the development of the blood halo assay were chosen
based on their prevalence in the literature, biological significance, and current clinical
application as mentioned. For the purpose of this project, the assay was developed primarily for
use with rabbit blood. However, a similar protocol was also developed for use with human blood
to compare fibrinolysis by different plasminogen activators to assess translational significance of
the treatments. It is possible that this kind of assay could even be used for personalized
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treatment. If a patient’s own whole blood could be used to determine which fibrinolytic activator
might have the greatest affect, this could potentially decrease the likelihood of failure with IPFT.
The plasminogen activators were assessed for activity prior to use in the blood halo assay.
The amidolytic activity assay was a chromogenic test used to detect the activity of the
plasminogen activators on the substrate which indicated the level of PLG activation. A PLG
activation assay was similarly used to detect the activation of PLG in the presence of the
plasminogen activators. For further confirmation, the plasminogen activators were analyzed on
an SDS-PAGE gel to determine the percent of active enzyme in each sample. These preliminary
tests showed that tPA and uPA were active. Therefore, this information supported the
confirmation of the role of tPA and uPA in fibrinolysis activation in the blood halo plate assay.
We have developed a high throughput 96-well plate-based BHA starting with determining the
appropriate volume of the whole blood halos. A plate was made with blood volumes ranging
from 1-25 µL to determine how the absorbance of the solution changed with blood halo volume.
The 25 µL blood halos indicated by Bonnard et. al were not suitable for the application with
rabbit blood due to absorbance values which were >4. The absorbance of blood halos with a
volume of 10 µL or greater resulted in absorbance values greater than 2 AU which translated to a
transmittance of less than 1% (Figure 8). Blood halos with a volume of ≤8 µL resulted in
absorbance values which were within the optimal range of detection. Unfortunately, a blood
volume of ≤8 µL was not suitable for the creation of uniform rings at the bottom of the 96-well
plate. 10 µL blood halos resulted in absorbance values on the upper end of the optimal detection
range which would be useful for detecting clot lysis. Being able to measure the increase in
absorbance as a result of clot lysis up to the limit of detection would allow for a more accurate
measurement of clot lysis over time. A volume of 10 µL also had enough volume to create full,
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reproducible blood halos at the bottom of the plate. Therefore, 10 µL blood halos were used in
the BHA.
The low volume of these blood halos is beneficial for personalized testing. A whole blood
patient sample less than 1 mL can be used to prepared over 3 plates containing 24 blood halos.
The current design of the assay assesses up to two plasminogen activators per 96-well plate.
Therefore, several plasminogen activators could be assessed using a whole blood sample of 1 mL
within approximately 24 hours after blood collection.
The stability of the assay was analyzed by monitoring fibrinolytic activity using prepared
plates. This analysis showed that rate of lysis did not appear to change significantly which
indicated that plates prepared could be stored without loss of activity over the period of 7 days
(Figure 12). This allowed for future plates to be run at different time points after preparation with
the confidence that reproducible results could be obtained even several days after preparation.
The stability of the assay allows for testing of different plasminogen activators as well as dose
responses in the setting of a single preparation. Thus, the BHA could be successfully used with
plates which have been prepared several days prior if needed. Therefore, if IPFT fails using one
plasminogen activator, another can be quickly assessed before treatment is changed.
During the development of the assay, we have elucidated the effect of thrombolysis using
thrombin and Dade Innovin. Dade Innovin reagent was used by Bonnard and colleagues for the
thrombotic droplet for human blood. Dade Innovin is composed of human tissue factor, synthetic
phospholipids, calcium, buffers, and stabilizers prepared using E. coli. However, in the rabbit
model, thrombin was used to assist in the clotting of the induced hemothorax. Therefore, we
compared the stability and reproducibility of the assay using blood halos prepared with Dade
Innovin or thrombin (0.01 U/µL). Using thrombin instead of Dade Innovin showed a difference
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in the stability of blood halos lysed by tPA (Figure 11) in rabbit blood. The rate of clot lysis
appeared more uniform using blood halos prepared with thrombin compared to blood clots made
with Dade Innovin. There was one outlier in the measurement of rate of fibrinolysis of blood
halos made with Dade Innovin. However, because the distribution of fibrinolysis was still more
uniform even without this outlier, the use of thrombin was selected as the preferred thrombotic
droplet for use in the assay for rabbit blood.
Different plasminogen activators have been used to facilitate clot lysis in humans. The use of
fibrinolytics has been applied to the treatment of hemothorax for several years [3, 4, 9, 12, 16].
Notably, tPA and uPA have been used to remove blood clots in patients suffering from acute
stroke [27]. However, the modes of action of tPA and uPA differ greatly. tPA activates PLG in
the presence of fibrin while the activation of PLG by uPA is independent of the presence of
fibrin [32]. We compared the activation of fibrinolysis with tPA versus uPA in rabbit blood
which indicated that uPA does not behave as expected. The rate of lysis of blood clots when uPA
was used to activate PLG was significantly lower compared to tPA. A similar trend was observed
with activation of fibrinolysis using uPA in rabbit blood even in the presence of human PLG.
This is interesting given that the same findings were not observed in human blood using the
BHA. Comparing the fibrinolytic activation of PLG with tPA versus uPA in human blood
indicated that PLG activation by uPA resulted in uniform clot lysis comparative to tPA (Figure
14). This result is significant as it could affect the utility of the rabbit hemothorax model in
studying certain fibrinolytic therapies. Although no animal model can exemplify the human
system with complete accuracy, it is nonetheless important to identify points of weakness [34].
Therefore, the blood halo assay has a considerably important role in supportive validation of the
model in translational indications of the rabbit model to the human condition.
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In conclusion, the rabbit hemothorax model recapitulates the clinical features of the human
hemothorax condition. Three injections of blood simulate continuous bleeding resulting in the
formation of retained hemothoraces in rabbits. The pleural injury observed upon post-mortem
examination demonstrated the similarities between the model and injuries associated with
retained hemothorax. The companion assay was developed for potential analysis of effective
fibrinolytic therapies prior to and in tandem with use in the rabbit model.
The assay can be used with a small sample of rabbit or human whole blood which makes the
assay both simple and efficient. Once a blood halo plate is prepared, it can be used several days
afterwards which can be beneficial for quick assessment of other IPFT options. Plates can also be
used to analyze more than one plasminogen activator at a time. The development of the assay
showed significant applicability which could lead to further investigative advances of the model
as well the possibility of personalized treatment. We have used two different plasminogen
activators to assess the utility of this assay in rabbit and human blood. We have shown that the
use of uPA promotes lysis over a longer time period compared to tPA in rabbit blood. In human
blood, it was shown that uPA and tPA were effective at promoting lysis of human clots quicker.
The effects of tPA and uPA were not a result of activator activity. It was shown that tPA and
uPA are equally active but result in different lysis times. This difference was lesser in human
halos compared to rabbit clots.
Consistency of plate preparation in the assay could be further improved through automation.
The I.DOT (Cellink) non-contact liquid dispensing tool which uses positive pressure to deposit
small volumes of solution could be used to increase precision and accuracy of the assay. Blood
halos which were prepared with the I.DOT showed similar lysis using the established assay
protocol modified for the machine. This would increase plate production with comparable results
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to the previous protocol. The use of the I.DOT, or machines like it, could potentially reduce the
effects of manual applications such as inconsistent blood halos, the presence of bubbles in halos,
and incomplete mixing of clotting factor and blood. Exploring the activities of other fibrinolytic
activators could also be beneficial in determining applicable fibrinolytic therapy for the model
which could also be optimized using the I.DOT. The translation between the rabbit model and
the human condition would be more quickly and just as accurately determined with the
automation of plate preparation testing. A combination of in vitro data collected using an assay
with the model of retained hemothorax would provide novel treatment studies which could lead
to the elucidation of appropriate treatment options.
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